Cargando…

FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas

BACKGROUND: Molecular profiling of gliomas is vital to ensure diagnostic accuracy, inform prognosis, and identify clinical trial options for primary and recurrent tumors. This study aimed to determine the accuracy of reporting the whole arm 1p19q codeletion status from the FoundationOne platform. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharaf, Radwa, Pavlick, Dean C, Frampton, Garrett M, Cooper, Maureen, Jenkins, Jacqueline, Danziger, Natalie, Haberberger, James, Alexander, Brian M, Cloughesy, Timothy, Yong, William H, Liau, Linda M, Nghiemphu, Phioanh L, Ji, Matthew, Lai, Albert, Ramkissoon, Shakti H, Albacker, Lee A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986056/ https://www.ncbi.nlm.nih.gov/pubmed/33778493 http://dx.doi.org/10.1093/noajnl/vdab017

Ejemplares similares

Erratum to: FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas
por: Sharaf, Radwa, et al.
Publicado: (2021)

Clinical and analytical validation of FoundationOne(®)CDx, a comprehensive genomic profiling assay for solid tumors
por: Milbury, Coren A., et al.
Publicado: (2022)

Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision‐Making for Patients with Advanced Solid Tumors
por: Takeda, Masayuki, et al.
Publicado: (2021)

PEDT-02 Clinical usage of NCC Oncopanel/FoundationOne CDx for pediatric/AYA patients with recurrent malignant brain tumors
por: Shibahara, Ichiyo, et al.
Publicado: (2020)

CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1–Wild-Type Tumor With Frequent CIC Genomic Alterations and 1p/19q-Codeletion
por: Williams, Erik A., et al.
Publicado: (2020)

Mutations in the TERC template sequence can be incorporated into the telomeres of human tumors
por: Sharaf, Radwa, et al.
Publicado: (2022)

FoundationOne CDx detected an uncovered variant of epidermal growth factor receptor exon 19 deletion by Oncomine Dx target test in a patient with lung adenocarcinoma
por: Takahashi, Hiroki, et al.
Publicado: (2023)

Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin
por: Woodhouse, Ryan, et al.
Publicado: (2020)

A pan-cancer landscape of telomeric content shows that RAD21 and HGF alterations are associated with longer telomeres
por: Sharaf, Radwa, et al.
Publicado: (2022)

A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas
por: Nghiemphu, Phioanh Leia, et al.
Publicado: (2012)

The Future Glioblastoma Clinical Trials Landscape: Early Phase 0, Window of Opportunity, and Adaptive Phase I–III Studies
por: Cho, Nicholas S., et al.
Publicado: (2023)

Molecular profiling of soft-tissue sarcomas with FoundationOne(®) Heme identifies potential targets for sarcoma therapy: a single-centre experience
por: Scheipl, Susanne, et al.
Publicado: (2021)

Improving B(0) Correction for pH-Weighted Amine Proton Chemical Exchange Saturation Transfer (CEST) Imaging by Use of k-Means Clustering and Lorentzian Estimation
por: Yao, Jingwen, et al.
Publicado: (2018)

BIMG-11. PHARMACODYNAMIC EVALUATION OF IDH AND EGFR INHIBITION IN HUMAN GLIOMAS USING MOLECULAR MRI
por: Ellingson, Benjamin, et al.
Publicado: (2021)

A pan-sarcoma landscape of telomeric content shows that alterations in RAD51B and GID4 are associated with higher telomeric content
por: Sharaf, Radwa, et al.
Publicado: (2023)

Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study
por: Yao, Jingwen, et al.
Publicado: (2020)

Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET
por: Tatekawa, Hiroyuki, et al.
Publicado: (2021)

Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series
por: Liu, Liang Yen, et al.
Publicado: (2019)

Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma
por: Murugesan, Karthikeyan, et al.
Publicado: (2021)

Prognostic value of O(6)-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas
por: Lam, Keng, et al.
Publicado: (2022)

Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study
por: Yao, Jingwen, et al.
Publicado: (2022)

A single-institution retrospective analysis of pathologically determined malignant transformation in IDH mutant glioma patients
por: Liu, Vicki, et al.
Publicado: (2023)

Genomic landscape of non‐small‐cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency
por: Ashok Kumar, Prashanth, et al.
Publicado: (2022)

Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI
por: Hagiwara, Akifumi, et al.
Publicado: (2022)

Pan-cancer analysis of the effect of biopsy site on tumor mutational burden observations
por: Papillon-Cavanagh, Simon, et al.
Publicado: (2021)

Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma
por: Patel, Kunal S., et al.
Publicado: (2020)

Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry
por: Chakhoyan, Ararat, et al.
Publicado: (2019)

Overlapping functions of Cdx1, Cdx2, and Cdx4 in the development of the amphibian Xenopus tropicalis
por: Faas, Laura, et al.
Publicado: (2009)

Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping
por: Banerjee, Pia, et al.
Publicado: (2015)

Daily functioning in glioma survivors: associations with cognitive function, psychological factors and quality of life
por: Van Dyk, Kathleen, et al.
Publicado: (2022)

Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations
por: Huang, Richard S.P., et al.
Publicado: (2020)

Frequency of false-positive FISH 1p/19q codeletion in adult diffuse astrocytic gliomas
por: Ball, Matthew K, et al.
Publicado: (2020)

Cdx1 and Cdx2 Exhibit Transcriptional Specificity in the Intestine
por: Grainger, Stephanie, et al.
Publicado: (2013)

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas
por: Leeper, Heather E., et al.
Publicado: (2015)

Diffusion MRI Characteristics After Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma
por: Chang, Warren, et al.
Publicado: (2015)

Characterization of cognitive function in survivors of diffuse gliomas using resting-state functional MRI (rs-fMRI)
por: Wang, Chencai, et al.
Publicado: (2021)

CDX1 and CDX2 Expression in Intestinal Metaplasia, Dysplasia and Gastric Cancer
por: Kang, Jung Mook, et al.
Publicado: (2011)

Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab
por: Leu, Kevin, et al.
Publicado: (2014)

Primary Leptomeningeal Oligodendroglioma, IDH-Mutant, 1p/19q-Codeleted
por: Ballester, Leomar Y., et al.
Publicado: (2018)

Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic
por: Li, Yan-Xi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_sjuef8720thl07pnt6dgf85qp6